As many of these inhibitors have already been proven to be clinically feasible and promising in inhibiting various cancers, their use to also induce NIS expression for adjuvant radioiodine treatment in addition to their direct inhibition of cancer cells may prove to be a novel and effective therapeutic strategy for selected non-thyroid cancers. Here, SLC5A5 is linked to cancer.